Objectives: The adenosine A2A antagonist istradefylline has been used to treat Parkinson disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of more than 2 hours. The purpose of this study is to assess the efficacy of 20 mg/d istradefylline in PD subjects experiencing an average daily OFF time of 3 hours or less.
A denosine A2A antagonists facilitate dopamine D2 receptors and improve motor function in animal models of Parkinson disease (PD). [1] [2] [3] However, the effects of A2A antagonists, unlike the effects of dopamine agonists, depend on the dose of L-DOPA. A2A antagonists potentiate the effects of suboptimal doses of L-DOPA without worsening dyskinesia, 1, 2 but that A2A antagonists with maximal doses of L-DOPA are less effective. 1 Previous randomized controlled trials (RCTs) of the A2A antagonist istradefylline compared with placebo as an adjunct to L-DOPA have reported that istradefylline significantly reduces both daily OFF time and ON-UPDRS-III, but the weighted mean difference in ON-UPDRS-III scores between 20 mg istradefylline and placebo is only −0.94. 4 Two RCTs have reported a significant improvement in ON-UPDRS-III scores with the administration of 40 mg/d of istradefylline, but the change from baseline was less than 5. [5] [6] [7] These RCTs included PD patients experiencing an average daily OFF time of 2 hours or more, and mean daily OFF time at baseline of more than 6 hours.
Here, we report the efficacy of istradefylline 20 mg/d as an adjunct to L-DOPA in PD subjects experiencing an average daily OFF time of 3 hours or less.
MATERIALS AND METHODS
This study was approved by the institutional review board of Hokkaido University. Fifteen patients found to satisfy the following criteria were enrolled into this retrospective study from November 2014 until November 2016. All 15 patients were diagnosed with idiopathic PD according to the United Kingdom PD Society Brain Bank Diagnostic Criteria with a modified Hoehn and Yahr stage between 1 and 3 (in the OFF state) and had an average daily OFF time of 3 hours or less. All subjects were receiving L-DOPA, and most of them (80%) were receiving other PD medications. Three patients 
RESULTS
At baseline, the subjects had shorter daily OFF times, lower doses of L-DOPA, and higher ON-UPDRS-III scores than those in previous RCTs (Table 1) . [5] [6] [7] Mean tremor subscores at baseline, 4, 8, and 12 weeks were 1.8, 0.7, 0.6, and 0.4, respectively. Mean rigidity subscores at baseline, 4, 8, and 12 weeks were 6.0, 2.8, 2.6, and 2.3, respectively. Mean akinesia subscores at baseline, 4, 8, and 12 weeks were 13.7, 7.7, 7.5, and 6.4, respectively. After 12 weeks of istradefylline administration, 11 patients (73%) showed more than 50% reductions in ON-UPDRS-III scores, and there was a significant reduction in ON-UPDRS-III scores (P < 0.001, Wilcoxon signed rank test). Improvement of ON-UPDRS-III was significantly correlated with baseline ON-UPDRS-III (Fig. 1 ) (Spearman correlation coefficient ρ = 0.7671, P < 0.001), but not with age, the duration of the disease, levodopa dosage, or ON-UPRDRS-III after 12 weeks administration of istradefylline. The mean ON-UPDRS-III score at end point was 12.1. Istradefylline tended to reduce the daily OFF time (P = 0.06). Dyskinesias developed in 2 patients and worsened in 2 other patients. Mean dyskinesia subscores at baseline, 4, 8, and 12 weeks were 0.3, 0.3, 0.2, and 0.4, respectively.
DISCUSSION
Twenty mg/d of istradefylline dramatically improved ON-UPDRS-III scores in PD patients with mild wearing-off.
The high responder rate in this study may help us to understand the factors influencing clinical effects of istradefylline on parkinsonian motor symptoms despite the small number of subjects.
L-DOPA dosage and age at disease onset have been reported to influence the occurrence of motor fluctuations. 8 One of the authors of this paper has previously reported that a chronic low-dose levodopa treatment proved satisfactory benefit with a low incidence of motor complications in Japanese PD patients. 9 Because the subjects in the present study had older age at disease onset and were treated with low dosages of L-DOPA despite higher ON-UPDRS-III scores than those in the previous RCTs, older age at onset and low (suboptimal) L-DOPA dosages may be associated with stable response to L-DOPA. It should be noted that more severely affected patients showed greater improvement in ON-UPDRS-III, which suggests that istradefylline can potentiate the effects of subthreshold dosage of L-DOPA above the threshold (Fig. 1) . Although a few previous RCTs have not shown a statistically significant reduction in OFF time because of a placebo effect, 6 The present study, as well as previous animal studies, suggests that adding istradefylline to low doses of L-DOPA and dopamine agonists is superior to the later use in PD patients treated with high doses of L-DOPA. It may be effective to administer istradefylline before the OFF symptoms progress.
Limitations
This study is limited by the fact that it is retrospective. Further evaluations on the early use of istradefylline combined with low doses of L-DOPA in double-blinded randomized controlled clinical trials are naturally needed.
